← All trials
NCT05155137
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2021
- Primary completion
- Dec 14, 2025
- Completion date
- Dec 14, 2026
- First posted
- Dec 13, 2021
- Last posted
- Dec 13, 2021
- Enrollment
- 12268
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital Moinhos de VentoLead sponsor
- Government of BrazilCollaborator
- Hospital Moinhos de VentoOverall official - principal investigator
- AUT University, Oakland, New ZealandStudy chair
- Danube University KremsStudy chair
- World Stroke OrganizationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.